Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 58 of 116

  1. Loncastuximab Tesirine

    ADC Therapeutics SA

    Relapsed or Refractory Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  2. Loncastuximab tesirine

    ADC Therapeutics SA

    Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  3. Loncastuximab tesirine

    ADC Therapeutics SA

    Diffuse Large B-Cell Lymphoma Refractory

    phase 2 small molecule completed

    1 trial

  4. Loncastuximab tesirine 150 µg/Kg

    ADC Therapeutics SA

    Marginal Zone Lymphoma

    phase 2 small molecule active

    1 trial

  5. Lonsurf / film-coated tablets for FGFR2b-positive, advanced or me…

    The George Institute

    FGFR2b-positive, advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction

    phase 2 small molecule active

    1 trial

  6. Low Molecular Weight Heparin (LMWH)

    Cardiff Oncology

    Cancer

    phase 2 small molecule terminated

    1 trial

  7. Low dose FRα vaccine

    Marker Therapeutics

    Breast Cancer

    phase 2 mab completed

    1 trial

  8. Low-dose ASA

    Atrium Therapeutics

    Germ Cell Tumor

    phase 2 small molecule active

    1 trial

  9. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Locally Advanced Soft Tissue Sarcoma

    phase 2 small molecule terminated

    1 trial

  10. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Small Cell Lung Cancer ( SCLC )

    phase 2 small molecule active

    1 trial

  11. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Refractory Ewing Sarcoma

    phase 2 small molecule active

    1 trial

  12. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Extensive-stage Small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Advanced Soft-tissue Sarcoma

    phase 2 small molecule active

    1 trial

  14. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Advanced Solid Tumor

    phase 2 small molecule terminated

    1 trial

  15. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Ewing Sarcoma

    phase 2 small molecule active

    1 trial

  16. Lutetium (177Lu) rhPSMA-10.1 injection

    Blue Earth Diagnostics Ireland Ltd

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  17. Luveltamab tazevibulin

    SUTRO BIOPHARMA, INC.

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule terminated

    1 trial

  18. Luveltamab tazevibulin

    SUTRO BIOPHARMA, INC.

    Lung Cancer

    phase 2 small molecule terminated

    1 trial

  19. Lynparza film-coated tablets for recurrent ovarian cancer wild t…

    Fondazione Telethon ETS

    recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes

    phase 2 small molecule active

    1 trial

  20. M22-132

    AbbVie Deutschland GmbH & Co. KG

    B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma

    phase 2 small molecule active

    1 trial

  21. M24-147

    AbbVie Deutschland GmbH & Co. KG

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  22. M24-311

    AbbVie Deutschland GmbH & Co. KG

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  23. M24-533

    AbbVie Deutschland GmbH & Co. KG

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  24. M24-633

    AbbVie Deutschland GmbH & Co. KG

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  25. M24-977

    AbbVie Deutschland GmbH & Co. KG

    Adenocarcinoma of the gastroesophageal junction

    phase 2 small molecule active

    1 trial

  26. M25-204

    AbbVie Deutschland GmbH & Co. KG

    Urothelial Carcinoma, Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  27. M25-709

    AbbVie Deutschland GmbH & Co. KG

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  28. M9140

    Serono Europe Limited

    Solid Tumors

    phase 2 small molecule active

    1 trial

  29. M9140

    Merck Sharp and Dohme

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  30. M9140

    Merck Sharp and Dohme

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  31. M9140

    Merck Sharp and Dohme

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  32. MB-106

    Moleculin Biotech

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  33. MB-huCART19.1

    AXIM BIOTECHNOLOGIES, INC.

    B-cell precursor ALL, B-cell Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  34. MB07133 300mg/m2/day

    LIGAND PHARMACEUTICALS INC

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  35. MCLA-128

    Partner Therapeutics Limited

    Solid Tumors

    phase 2 small molecule active

    1 trial

  36. MDNA11

    Medicenna Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  37. MDNA11-01

    Medicenna Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  38. ME-CLN-002

    CASI Pharmaceuticals

    Carcinoid Tumor

    phase 2 small molecule completed

    1 trial

  39. MEDI4736

    AstraZeneca

    Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

    phase 2 small molecule completed

    1 trial

  40. METFORAL 850 mg compresse rivestite con film

    Fondazione Telethon ETS

    Triple negative breast cancer

    phase 2 small molecule active

    1 trial

  41. METFORMIN

    Istituto Gentili S.r.l.

    bone sarcoma

    phase 2 small molecule active

    1 trial

  42. MIA2019/CT/258

    The George Institute

    melanoma brain metastases

    phase 2 small molecule active

    1 trial

  43. MIBIOTIMI

    The George Institute

    Breast cancer

    phase 2 other active

    1 trial

  44. MIE

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 other active

    1 trial

  45. MITO 25.1

    Fondazione Telethon ETS

    Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer.

    phase 2 small molecule active

    1 trial

  46. MITO 35a

    Fondazione Telethon ETS

    BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer

    phase 2 small molecule active

    1 trial

  47. MITO VULVA-01

    Fondazione Telethon ETS

    vulvar cancer

    phase 2 small molecule active

    1 trial

  48. MK-1022-010

    Merck Sharp and Dohme

    High Risk Early-Stage Triple Negative Breast Cancer (TNBC) or Hormone Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR-low+/HER2-) Breast Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.